Alcon pairs 5% Q3 sales growth with a Neurotech purchase as eye-care dealmaking widens
Alcon announced its planned Neurotech Pharmaceuticals acquisition alongside $2.7bn in third-quarter sales, while smaller biotechs show the range of exits and funding routes now in play.
What happened
Alcon reported third-quarter sales up 5% to $2.7bn and nine-month sales of $8.2bn. The company attributed growth to dry eye products and surgical equipment launches. In the same update it highlighted its planned purchase of Neurotech Pharmaceuticals.
The material available to us does not include the purchase price, the structure, the expected closing timetable, or details of Neurotech's assets or financials. Any assessment of valuation or accretion is therefore premature. What can be analysed is the context: the timing, the commercial base Alcon is building from, and how the deal sits against other eye-care and small-cap transactions this week.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Alcon third-quarter sales rise 5% to $2.7bn; Neurotech acquisition announced Alcon Inc · 10 Nov 2026
- MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first Macrogenics Inc · 13 Nov 2026
- Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient Xenetic Biosciences, Inc. · 13 Nov 2026
- Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review Longeveron Inc. · 12 Nov 2026
- Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage Silence Therapeutics plc · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.